ArticleHardwareX2025
Real-time converter of intermittent-scanned glucose sensors to continuous glucose monitors with potential future applications for insulin delivery.
Article in HardwareX, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This paper presents the development of a transmitter that transforms intermittent glucose sensors (isCGM) into a continuous and real-time glucose monitoring system (c-rtCGM), a key component in automated insulin delivery systems. The transmitter enhances the capabilities of conventional intermittent sensors by leveraging Near Field Communication (NFC) technology to capture raw glucose value and automatically transmit it via Bluetooth Low Energy (BLE-Bluetooth 4.2 Dual-Mode) to a smart device every five minutes. A specialized glucose monitoring application converts the raw values to blood glucose by applying a calibration based on a static linear model and a capillary blood glucose measurement. The accuracy and performance of the c-rtCGM were validated through a study involving 37 participants with type 1 diabetes, demonstrating its reliability compared to commercial transmitters. Values reported by the c-rtCGM system compared with the isCGM monitor system resulted in an overall mean average relative difference (MARD) around 9%. During the trial, the c-rtCGM system achieved a data transmission success rate of 96%, and only 2316 connection failures were recorded from the 66525 total connection attempts, indicating a high level of communication stability. The transmitter battery life lasted an average of 6.5 days, showing that it is necessary to recharge only once for the duration of the sensor (14 days). The main advantages of this customized transmitter, in contrast with the commercial versions, are reliability, cost, and the flexibility of its software, since its processor (an ESP32) can be easily programmed to fulfill other helpful tasks in managing glucose levels with automated insulin delivery systems.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.